In multiple myeloma, malignant plasma cellsfrom most patients with active disease proliferate spontaneously when cultured for 5 days in vitro. This spontaneous proliferation is related to the endogenous production of interleukin-6 (IL-6), the major myeloma-cell growth factor. A 50% inhibitory dose ( I 0 0 U/mL) of human recombinant 7-interferon (hry IFN) blocked the proliferation of myeloma cells almost completely in all 1 9 patients analyzed. This inhibition was not caused by suppression of endogenous IL-6 production and was also observed in the presence of an excess of hrlL-6. hry-IFN was also completely inhibitory in four human UMAN MULTIPLE myeloma (MM) is a B-cell neo-H plasia characterized by the accumulation of malignant plasma cells, primarily in bone marrow (BM). In most patients, myeloma cells are mainly nonproliferating mature plasma cells, and proliferating tumor cells are restricted to a tiny population (about 5%) of plasmablasts. The extent of this proliferating plasmablastic compartment has been shown to be one of the strongest prognostic factors for myeloma progression and unresponsiveness to conventional treatments.1*2 Several groups, including ours, have shown that interleukin-6 (IL-6) is an essential myeloma-cell growth factor in ~i t r o~-~ and that the proliferative response of myeloma cells to IL-6 in vitro is correlated with their proliferative capacity in vivo.' IL-6 is also involved in myeloma progression in vivo. Indeed, IL-6 is overproduced in patients with MM,3,8 in correlation with disease severity and patient s u r v i~a l ,~~l~ and the treatment of patients with anti-IL-6 monoclonal antibodies (MoAbs) blocks myeloma-cell proliferation in vivo."
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In this study, we show that y-IFN can almost completely inhibit the IL-6-dependent growth of freshly explanted myeloma cells and human myeloma cell lines (HMCL). We also show that one of the mechanisms of this inhibition is a downregulation of the expression of gp80 IL-6-binding protein.
MATERIALS AND METHODS
We studied the in vitro effects of human recombinant y-IFN (hry-IFN) on BM mononuclear cells (BMMC) of 2 1 patients with MM (IO at diagnosis, 1 I during relapse) and on peripheralblood mononuclear cells (PBMC) of five patients with secondary plasma-cell leukemia (PCL), after obtaining their informed consent. The diagnostic criteria were those of the Southwest Oncology Group.18 Six patients were stage I, 3 stage 11, 14 stage IIIA, and 3 stage IIIB. Sixteen patients had an IgG myeloma, 7 an IgA myeloma, and 3 were Bence Jones. The sex ratio (M:F) was 1:4 and the mean age 64 years (range, 41 to 81).
The IL-6-dependent human myeloma cell lines XG-1, XG-2, XG-3, and XG-5 were obtained in our laboratory, as described elsewhere," and grown in RPMI 1640 (GIBCO BRL, Cergy-Pontoise, France) supplemented with 10% fetal calf serum (FCS) (GIBCO BRL), 5 X mol/L 2-mercaptoethan01, 2 mmol/L L-glutamine, and 1 ng/mL of hrIL-6. The IL64ependent B9 heterohybridoma cell line, a kind gift from L.A. Aarden (Amsterdam, The Netherlands), was used as IL6 bioassay. One unit of hrIL-6, defined as the amount inducing half-maximal proliferation, corresponded to 1 pg of hrIL-6. hrIL6 was kindly provided by N. Determination of the percentages of myeloma cells in S phase. Myeloma cells were characterized by intracytoplasmic immunofluorescence with anti-r or anti-)\ Ig light-chain antibodies directly coupled to fluorescein (FITC; Kallestadt, Austin, TX). The percentages of myeloma cells in S phase were determined by using an anti-bromodeoxyuridine MoAb (Bu-l), as previously described.' For statistical analyses, at least 1,000 myeloma cells were analyzed.
Cells were washed twice, incubated in RPMI 1640 supplemented with 10% FCS for 3 hours at 37"C, and washed again. Cells were then cultured in 96-well flatbottomed microtiter plates at 5 X lo3 cells/well in RPMI 1640 containing 10% FCS with various concentrations of hry-IFN for 2 to 5 days depending on the HMCL. Eight hours before ending the culture, 0.5 pCi per well of 'H-thymidine (specific activity: 25 Ci/mmol; C.E.A., Saclay, France) was added and 'H-thymidine incorporation was determined as previously described.'
XG-1 and XG-5 cells were incubated for various lengths of time with or without addition of 100 U/mL of hry-IFN in culture medium containing 1 ng/mL of hrIL-6. Total RNA was extracted from cells by 2 mol/L LiCl precipitation and purified by phenol/CHzClz extractions. Twenty micrograms of RNA per lane was run on 10% formaldehyde/l% agarose gel and transferred onto nitrocellulose filters (Schleicher and Schuell, Paris, France). Hybridizations were performed with the IL-6 receptor (IL-6R) probe labeled by the random priming method (Boehringer Mannheim, Meylan, France) with (u-'*P (dCTP). Standardization of the amount of mRNA was obtained by rehybridizing filters with a GAPDH probe labeled by nick-translation (Boehringer Mannheim). Filters were exposed to Kodak XAR5 films (Eastman Kodak, Rochester, NY) at -70°C and autoradiograms were scanned on a dual-wavelength TLC CS-930 scanner (Shimatzu, Japan). The relative amount of IL-6R mRNA was calculated after standardization with the amount of GAPDH mRNA in each lane. Modulation of IL-6R gene expression by y-IFN was evaluated after comparison with the control group (cells incubated without y-IFN), and results are expressed as a percent of the control group.
Cells were cultured for 24 hours with hrIL-6 (control) or hrIL-6 and various concentrations of hry-IFN, harvested, and then resuspended in phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin (BSA). Cells, IO6, in 100 pL of PBS were then incubated for I hour at +4"C with either 1 pg of MT18 MoAb or 1 pg of a control mouse Ig. The MT18 MoAb recognizes the gp80 a chain of the IL-6R complex, free or bound to IL6. After several washings, cells were incubated with FITC-labeled goat anti-mouse Ig antibodies (Immunotech, Marseilles, France), and fluorescence was analyzed with an Ortho 50H cytofluorograph (Westwood, MA).
For a given patient, the myeloma-cell labeling indexes determined in the cultures supplemented with hry-IFN or not were compared by using the chi-square test. When the whole population of myeloma patients was considered, the mean labeling indexes were compared using the paired t-test.
Prolifeation assay for HMCL. Northern blot analysis.
Immunostaining with anti-ZL-6R MoAb. For The specificity of inhibition by y-IFN was further demonstrated by experiments including preincubation of hry-IFN with an anti-y-IFN MoAb or an irrelevant isotypematched control MoAb before addition to the cultures. As shown in Fig 1, the anti-y-IFN MoAb abrogated the inhibitory effect of y-IFN on myeloma-cell proliferation.
Statistical analyses.

RESULTS
Effect
Effect of y-IFN on endogenous production of IL-6 by BM cells. Since spontaneous myeloma-cell proliferation is mediated by the endogenous IL-6 produced in culture^,^ we investigated whether y-IFN could inhibit this production. As indicated in Table 2 , addition of hry-IFN at concentrations of 100 U/mL or 1,000 U/mL did not significantly inhibit or stimulate IL-6 production in BM cultures. Moreover, the inhibitory effect of y-IFN on myeloma cells could not be reversed by adding high concentrations ( 1,000 U/mL) of hrIL-6 at the start of culturing (Fig 2) .
To investigate whether the inhibitory effect of y-IFN on myeloma cells was direct or indirect, we took advantage of our recent development of several HMCL whose growth is completely dependent on addition of exogenous IL-6, similar to that of freshly explanted myeloma cells. As shown in Figs 3 and 4 , the proliferation and growth of the four HMCL were draEffect of y-IFN on IL-6-dependent HMCL. matically inhibited by y-IFN, with a 50% inhibitory dose (ID5,,) ranging from 10 to 50 U/mL. Without addition of IL-6, the HMCL did not grow (Fig 4) and hry-IFN had no stimulatory activity.
Effect of y-IFN on expression of gpS0 IL-&binding protein in HMCL. The effect of hry-IFN on the expression of membrane IL-6-binding protein gp80 was analyzed on four HMCL (XG-1, XG-2, XG-3, and XG-5) by immunostaining For personal use only. on October 3, 2017. by guest www.bloodjournal.org From using the MT18 MoAb, which recognizes both free and IL-6-bound gp80. Representative profiles of immunofluorescence obtained with XG-1 and XG-2 HMCL are shown in Fig 5, and detailed results for the four HMCL are summarized in Table 3 . The four HMCL expressed significant amounts of membrane gp80. When cells were cultured for 24 hours with 100 U/mL y-IFN, a significant decrease in the membrane expression of gp80 was found (28% to 67%), an effect that was more marked with 1,000 U/mL y-IFN (47% to 73%). Increasing culture durations with y-IFN for 48 or 72 hours did not result in a further decrease in the amount of gp80 (data not shown). The downregulation of gp80 expression by Cells were cultured for 24 hours with 1 ng/mL of hrlL-6 and various concentrations of hrr-IFN (0 U/mL, 100 U/mL, and 1,000 U/mL), then washed and incubated with anti-gp80 MT18 MoAb further revealed with an FITC-conjugated goat anti-mouse lg. Results are mean fluorescence intensities and percentages of positive cells. The percentage of fluorescence intensity decrease for cells incubated with yIFN compared to cells not incubated with hry-IFN is indicated in parentheses.
y-IFN was also evidenced at the RNA level for XG-1 and XG-5 HMCL. An 80% to 90% decrease in the amount of gp80 mRNA was observed after 6 to 9 hours of incubation with 100 U/mL y-IFN (Fig 6) . The XG-1 cells cultured with hry-IFN could survive for as long as 4 days, and no further increase of IL-6R mRNA up to the baseline level was observed during this period (Fig 6) . Concerning XG-5 cells, analyses were performed during only 24 hours because hry-IFN, in this experiment, induced a decrease of cell viability after We show here that hry-IFN did not inhibit this endogenous IL-6 production, and that its inhibitow effect was still observed in the presence of exogenous hrIL-6. Moreover, by using our myeloma cell lines whose is campletely dependent on exogenous IL6, similar to that of freshly explanted myeloma ce11s333'9 we show that h r y -I m acts directly on pure myeloma cells and completely inhibits their Furthermore, we show that hry-IFN inhibition of myeloma-cell proliferation is associated with a significant decrease in the expression of IL-6-binding gp80 protein, both at the RNA and protein levels. A downregulation of IL-6R expression may explain why y-IFN decreases the IL-6-mediated production of acute-phase proteins by hepatocytes16 and inhibits cytokine-mediated bone resorpti~n,'~.'~ a process recently shown to be completely dependent on endogenous IL-6 produced by bone t i~s u e . '~. '~ This central role of IL-6 in cytokine-mediated bone resorption offers a good biologic rationale to explain why bone resorption is a major clinical problem in MM, a disease characterized by hyperproduction of IL-6 by the tumoral environment in vivo.'."
Thus, y-IFN is a potent inhibitor of two processes mediated by IL-6 (myeloma-cell proliferation and bone resorption) that are major characteristics of MM. In a previous study using y-IFN as a single agent, no response was observed in I3 of I5 patients. In one patient, the disease has remained stable for over 16 months, with a steady improvement in the values of normal Ig in the serum.24 There does seem to be a paradox between our in vitro data and this prior clinical experience. As the effects of y-IFN on myeloma-cell proliferation and bone resorption in vivo were not evaluated in this previous clinical study, it is not certain whether our findings are restricted to in vitro experiments or could also be observed in vivo. There is no evident reason for predicting a lack of hry-IFN effect in vivo regarding y-IFN doses. Indeed, the doses active on myeloma cells in vitro (IDSo ranging from 20 to For personal use only. on October 3, 2017. by guest www.bloodjournal.org From 100 U/mL) are in the range of those usually active on other lymphoid cells.22 Moreover, in patients injected with y-IFN, local concentrations of this cytokine in tissues, especially BM, are likely to be higher than the circulating concentrations estimated in pharmacokinetic experiment^.^^ Indeed, y-IFN binds with high affinity and in an active form to a great number of heparan sulfate proteoglycans in the extracellular matrix.26 For these reasons, we believe that it is important to investigate seriously whether y-IFN could also block myeloma cell proliferation and/or bone resorption in vivo as it does in vitro, in which case this cytokine could be useful for improving anti-IL-6 therapies (dexamethason, IL-1 receptor antagonist, anti-IL-6 antibodies, anti-IL-6 receptors, etc) for this disease."
